NTRA stock surges after big earnings beat and guidance hike. TIM BOHEN - UPDATED AUG. 7, 2026, 12:32 PM ET Natera Inc. stocks have been trading up by 18.71 percent after strong clinical data boosted investor confidence in its diagnostics portfolio. Key takeaways. * Q2 revenue came in at $752.8M, crushing the $661.2M consensus and signaling powerful volume growth for NTRA's testing business. * The company reported a Q2 loss of $0.47 per share, slightly better than expectations for a $0.49 loss, showing gradual margin improvement. * Full-year 2026 revenue guidance was raised to $2.85B-$2.91B, above both the prior $2.74B-$2.82B range and the $2.80B Street forecast. * Shares of NTRA jumped more than 12% in after-hours trading after the Q2 beat and outlook boost. * The Signatera minimal residual disease test was submitted to Japan's PMDA for use in muscle-invasive bladder cancer, expanding on existing approval in colorectal cancer. Live Update At 12:32:13 EDT: On Friday, August 07, 2026 Natera Inc. stock [NASDAQ: NTRA] is trending up by 18.71%! Discover the key drivers behind this movement as well as its expert analysis in the detailed breakdown below. Quick financial overview. Natera Inc. (NTRA) just delivered the kind of quarter momentum traders look for. Q2 revenue hit $752.8M, far ahead of the $661.2M consensus. That kind of top-line beat tells you demand for NTRA's genetic and oncology testing remains strong and is likely accelerating. Yes, NTRA is still unprofitable. The company posted a Q2 loss of $0.47 per share, but even that was slightly better than the expected $0.49 loss. When a growth name pairs big revenue upside with a narrower loss, traders read it as operating leverage starting to kick in. On the chart, NTRA has been in a steady uptrend. The stock closed at $265.38 on 2026/08/06 and ripped to $315.50 on 2026/08/07, a powerful post-earnings move that confirms buyers are in control. Intraday, the 5-minute tape shows tight trading between roughly $311 and $318, with dips getting bought and the stock finishing near highs. That kind of price action often reflects strong institutional interest. Longer term, Natera is a high-valuation name, with a rich price-to-sales ratio around 15.7 and negative returns on equity. For traders, that means the story is all about growth and execution. As long as NTRA keeps beating revenue expectations and tightening losses, the market tends to forgive red ink. Why traders are watching Natera right now. NTRA lit up screens after its latest earnings release, and for good reason. This wasn't a mild "in line" report. Natera smashed expectations, and the stock's more than 12% after-hours jump shows the surprise was real. The core driver is simple: growth. Natera's $752.8M Q2 revenue didn't just beat the $661.2M estimate; it blew past it. For a diagnostics and genomics name, that scale of upside usually means testing volumes are running hot, especially in oncology where pricing is stronger. Traders who focus on momentum know that when a company consistently outperforms on the top line, funds often chase the story. Earnings were still negative, but NTRA's $0.47 per-share loss came in a bit better than the expected $0.49 loss. That may sound small, yet it signals operating discipline. Combine that with a gross margin above 65%, and you have a setup where every new dollar of revenue can improve the bottom line over time. The bigger tell, though, is guidance. Natera raised its 2026 revenue outlook to $2.85B-$2.91B, up from $2.74B-$2.82B and clearly above the $2.80B consensus. When management pushes guidance above Wall Street, it's a loud statement of confidence. Traders in NTRA are reacting to that, not just the rear-view numbers. On top of earnings, Natera is extending its global reach. The company submitted its Signatera minimal residual disease test to Japan's PMDA for approval in muscle-invasive bladder cancer, building on existing PMDA approval in colorectal cancer. That move, backed by recent U.S. FDA approval and NCCN guideline inclusion for the same indication, deepens the moat around Signatera. For growth-focused traders, expanding regulatory footprints like this support the idea that NTRA's oncology franchise has a long runway. Conclusion. For active traders, NTRA is a textbook example of a catalyst-driven move. Strong Q2 revenue, a slightly better-than-feared loss, and a clear hike in full-year guidance have combined with a high-momentum chart. The stock's jump from the mid-$260s to the mid-$310s in one day tells you how underpriced the growth story may have been heading into the print. At the same time, Natera remains a high-risk, high-reward name. The company is unprofitable, with negative returns on assets and equity, and a rich valuation that depends on continued execution. The balance sheet, with a current ratio around 3 and modest leverage, gives NTRA room to keep investing, but traders must remember this is still a growth play, not a steady cash cow. As Tim Bohen, lead trainer with StocksToTrade says, "A good trade setup checks all the boxes - volume, trend, catalyst. Don't trade if you're missing pieces of the puzzle." That framework applies here: NTRA's liquidity, chart strength, and fundamental news all aligned to create a compelling short-term trading opportunity. The Signatera expansion into Japan via the PMDA submission reinforces Natera's strategy: build a global oncology diagnostics platform anchored in strong regulatory support and clinical guidelines. If that strategy continues to work, the raised 2026 revenue range of $2.85B-$2.91B may not be the last upgrade. For those studying NTRA as a trading case study, the message lines up with what Tim Sykes teaches: "React to the news, don't predict it. Let the earnings, the guidance, and the price action confirm the trade, and always be ready to cut losses fast if the story changes." This analysis is for educational and research purposes only and is not advice. This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Its coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, StocksToTrade, Inc. break down the events that can spark significant price action. Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead. Once your watchlist is set, take the next step and trade with confidence using StocksToTrade's robust platform. Don't miss out - grab your 14-day trial for just $7 and experience the edge you need to thrive in today's fast-paced markets. Why top traders call it "money Monday" If you hate Mondays... That's probably because you don't know about MONEY MONDAYS. Most traders don't know this but... There's a unique kind of trade you can make every Monday morning... That often delivers more gains in 1 day than most people see in a year. Like on one recent Monday... When you could have ridden MSS for a +149% in one day. Even with a small $1,000 starting stake... that's almost $1,500 profit potential! Of course, I can't promise you future returns or against losses... But it's almost that time again. Will you join StocksToTrade, Inc.?

Natera reported second-quarter revenue of $752.8 million, beating analyst estimates by 13.6% and marking 37.7% year-on-year growth. The genetic testing company's shares jumped 16.3% following the results. The company's full-year revenue guidance of $2.88 billion came in 3% above analysts' expectations. Natera posted a GAAP loss of $0.47 per share, slightly better than the estimated loss of $0.51. Sales volumes rose 22.4% year on year, whilst operating margin improved to -10.1% from -20.2% in the same quarter last year. The company processed 1.04 million tests in the quarter. Analysts expect Natera's revenue to grow 11.9% over the next 12 months, representing a deceleration from recent growth rates.

Natera (NASDAQ:NTRA) insider John Fesko sells 782 shares. July 29, 2026 Key points. * Natera insider John Fesko sold 782 shares for approximately $203,703 at an average price of $260.49, reducing his position by 0.42%. The sale occurred under a pre-arranged Rule 10b5-1 plan to cover tax withholding tied to vested equity awards. * Natera shares traded at $253.82, up 0.6%, with a $36.35 billion market capitalization. The stock has traded between $131.81 and $288.04 over the past year. * Analysts maintain a generally positive outlook, with a consensus rating of "Moderate Buy" and an average price target of $267.83; institutional investors own 99.90% of the company's stock. * Interested in Natera? Here are five stocks we like better. Natera, Inc. (NASDAQ:NTRA - Get Free Report) insider John Fesko sold 782 shares of the stock in a transaction that occurred on Monday, July 27th. The shares were sold at an average price of $260.49, for a total value of $203,703.18. Following the transaction, the insider owned 185,000 shares in the company, valued at approximately $48,190,650. This trade represents a 0.42% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. John Fesko also recently made the following trade(s): * On Tuesday, July 28th, John Fesko sold 931 shares of Natera stock. The stock was sold at an average price of $254.07, for a total transaction of $236,539.17. * On Tuesday, May 26th, John Fesko sold 1,438 shares of Natera stock. The stock was sold at an average price of $202.84, for a total transaction of $291,683.92. * On Friday, May 1st, John Fesko sold 291 shares of Natera stock. The stock was sold at an average price of $206.16, for a total transaction of $59,992.56. Natera trading up 0.6%. NASDAQ:NTRA traded up $1.60 during mid-day trading on Wednesday, hitting $253.82. 925,147 shares of the company's stock traded hands, compared to its average volume of 1,091,572. The firm has a 50 day moving average of $244.16 and a two-hundred day moving average of $221.65. The firm has a market capitalization of $36.35 billion, a price-to-earnings ratio of -155.72 and a beta of 1.51. Natera, Inc. has a 12 month low of $131.81 and a 12 month high of $288.04. Institutional trading of Natera. Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Horizon Investments LLC lifted its position in shares of Natera by 22.0% during the 4th quarter. Horizon Investments LLC now owns 244 shares of the medical research company's stock worth $56,000 after buying an additional 44 shares during the period. Sound Income Strategies LLC raised its stake in Natera by 20.0% during the fourth quarter. Sound Income Strategies LLC now owns 270 shares of the medical research company's stock worth $62,000 after acquiring an additional 45 shares in the last quarter. Savvy Advisors Inc. lifted its holdings in shares of Natera by 3.1% during the fourth quarter. Savvy Advisors Inc. now owns 1,541 shares of the medical research company's stock valued at $353,000 after acquiring an additional 46 shares during the period. Parallel Advisors LLC boosted its stake in shares of Natera by 5.5% in the 1st quarter. Parallel Advisors LLC now owns 905 shares of the medical research company's stock valued at $181,000 after purchasing an additional 47 shares in the last quarter. Finally, First Horizon Corp grew its holdings in shares of Natera by 5.5% in the 1st quarter. First Horizon Corp now owns 982 shares of the medical research company's stock worth $196,000 after purchasing an additional 51 shares during the last quarter. Institutional investors own 99.90% of the company's stock. Wall Street analyst weigh in. Several analysts have issued reports on NTRA shares. Barclays decreased their price target on shares of Natera from $280.00 to $260.00 and set an "overweight" rating on the stock in a research report on Wednesday, June 24th. Wells Fargo & Company lifted their target price on Natera from $215.00 to $220.00 and gave the stock an "equal weight" rating in a research report on Friday, May 8th. Wolfe Research assumed coverage on Natera in a research note on Tuesday, June 2nd. They set an "outperform" rating and a $260.00 price target on the stock. Sanford C. Bernstein started coverage on Natera in a report on Friday, June 26th. They issued an "outperform" rating and a $310.00 price target for the company. Finally, JPMorgan Chase & Co. raised their price objective on Natera from $260.00 to $265.00 and gave the stock an "overweight" rating in a research report on Friday, May 8th. Three research analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating, three have given a Hold rating and two have assigned a Sell rating to the company's stock. According to MarketBeat, the stock has an average rating of "Moderate Buy" and an average price target of $267.83. About Natera. Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients. Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection. This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected]. Before you consider Natera, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Natera wasn't on the list. While Natera currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys. Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.